Skip to main contentSkip to navigationSkip to search

Press release

Camurus Annual Report for 2018

15 April 2019 | Regulatory

Lund, Sweden — 15 April 2019 — Camurus (CAMX) today announces that the Annual Report for 2018 now is available at the company’s website: 

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37

TypeError: Cannot read properties of undefined (reading 'url')